On February 1, 2024 Spyre Therapeutics, Inc. announced that, Alison Lawton resigned from the Board, effective immediately. Ms. Lawton?s resignation was not the result of any disagreements with the Company relating to the Company?s operations, policies or practices. the company also announced the appointment of Mark C. McKenna as a Class I director.

Mr. McKenna's track record of corporate leadership, product development, and value creation, particularly in IBD. The Company looks forward to his guidance as it advances its potentially antibodies targeting a4ß7 and TL1A into clinical trials this year. Mr. McKenna, age 44, has served as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases, since June 2023.

Mr. McKenna most recently served as the President and Chief Executive Officer and as a member of the board of directors of Prometheus Biosciences, Inc. (?Prometheus?), a clinical stage biotechnology company, from September 2019 to June 2023, when Prometheus was acquired by Merck & Co., Inc., and as Chairman of the board of directors from August 2021 to June 2023. Prior to Prometheus, he served as President of Salix Pharmaceuticals, Inc., a pharmaceutical company and wholly-owned subsidiary of Bausch Health Companies, Inc., from March 2016 through August 2019. Prior to Salix, Mr. McKenna spent more than a decade in various roles with Bausch + Lomb, also a division of Bausch, most recently as Senior Vice President and General Manager of its U.S. Vision Care business.

Before joining Bausch + Lomb, he held several positions with Johnson & Johnson. Mr. McKenna has served as chair of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE) since August 2023. Mr. McKenna holds a B.S. in Marketing from Arizona State University and an M.B.A. from Azusa Pacific University.